AstraZeneca's Saphnelo Reduces Autoimmune Disease Activity in Phase 3 Study

MT Newswires · 4d ago
02:33 AM EST, 01/06/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Tuesday that its monoclonal antibody Saphnelo met key secondary endpoints in its late-stage trial for systemic lupus erythematosus. The phase 3 Tulip-Sc trial showed that patients who used Saphnelo had reduced disease activity, achieved a sooner British Isles Lupus Assessment Group-based Composite Lupus Assessment response, and had their first disease flare-up delayed. The pharmaceutical company added that the treatment's safety profile was also well tolerated and its safety profile was consistent with its previous clinical profile.